Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/10/22 07:46:01」(JST)

wiki en

Porfimer sodium, sold as Photofrin, is a photosensitizer used in photodynamic therapy and radiation therapy and for palliative treatment of obstructing endobronchial non-small cell lung carcinoma and obstructing esophageal cancer.

Porfimer is a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units.^[1] In practice, a red light source emitting at 630 nm is used to excite the Porfimer oligomers.^[2]

Porfimer is Haematoporphyrin Derivative (HpD) (See PDT).

Approvals and indications

It was approved in Canada in 1993 for the treatment of bladder cancer.^[2] It was approved in Japan in 1994 (for early stage lung cancer?).^[2] It was approved by the U.S. FDA in December 1995 for esophageal cancer, and in 1998, it was approved for the treatment of early non-small cell lung cancer.^[2]

In August 2003 the FDA approved its use for Barrett's esophagus.^[3]

References

^ "Porfimer injection Prescribing information" (PDF).
^ ^a ^b ^c ^d "Photodynamic Therapy (PDT) for Lung Cancers". 2006.
^ "FDA Patient Safety News: Show #20, October 2003". October 2003. Retrieved 2009-08-17.

External links

Photofrin
Photofrin marketing info
Side effects of PDT with Photofrin
History of Photofrin

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. バレット食道のアブレーションのための光線力学療法 photodynamic therapy for ablation of barretts esophagus
2. 早期胃癌：治療、自然経過、および予後 early gastric cancer treatment natural history and prognosis
3. 筋層非浸潤性膀胱癌の治療 treatment of non muscle invasive bladder cancer
4. 皮膚扁平上皮癌の治療および予後 treatment and prognosis of cutaneous squamous cell carcinoma
5. 食道癌の内視鏡的緩和 endoscopic palliation of esophageal cancer

English Journal

Long term efficacy of Photodynamic Therapy (PDT) as an ablative therapy of high grade dysplasia in Barrett's oesophagus.

Gray J1, Fullarton GM.Author information 1Department of Oesophagogastric Surgery, Glasgow Royal Infirmary, 84 Castle St., Glasgow G4 0SF, United Kingdom. Electronic address: jojo.gray@gmail.com.AbstractBACKGROUND: Barrett's high grade dysplasia (HGD) is a pre-malignant condition which requires treatment with either oesophagectomy or ablative endoscopic therapy. Endoscopic ablative techniques have evolved through Photodynamic Therapy (PDT) to more recently radiofrequency ablation (RFA). Although RFA has superseded PDT due to improved efficacy and safety profile there remains a significant cohort of patients previously treated by PDT where the long term outcome is unclear. This study's aim was to assess the long term efficacy of PDT in patients with Barrett's HGD.
Photodiagnosis and photodynamic therapy.Photodiagnosis Photodyn Ther.2013 Dec;10(4):561-5. doi: 10.1016/j.pdpdt.2013.06.002. Epub 2013 Sep 17.
BACKGROUND: Barrett's high grade dysplasia (HGD) is a pre-malignant condition which requires treatment with either oesophagectomy or ablative endoscopic therapy. Endoscopic ablative techniques have evolved through Photodynamic Therapy (PDT) to more recently radiofrequency ablation (RFA). Although RF
PMID 24284112

Photodynamic therapy vs radiofrequency ablation for Barrett's dysplasia: efficacy, safety and cost-comparison.

Ertan A1, Zaheer I, Correa AM, Thosani N, Blackmon SH.Author information 1Atilla Ertan, Nirav Thosani, Ertan Digestive Disease Center, Memorial Hermann Hospital, Texas Medical Center, Houston, TX 77030, United States.AbstractAIM: To compare effectiveness, safety, and cost of photodynamic therapy (PDT) and radiofrequency ablation (RFA) in treatment of Barrett's dysplasia (BD).
World journal of gastroenterology : WJG.World J Gastroenterol.2013 Nov 7;19(41):7106-13. doi: 10.3748/wjg.v19.i41.7106.
AIM: To compare effectiveness, safety, and cost of photodynamic therapy (PDT) and radiofrequency ablation (RFA) in treatment of Barrett's dysplasia (BD).METHODS: Consecutive case series of patients undergoing either PDT or RFA treatment at single center by a single investigator were compared. Thirty
PMID 24222954

Treatment of astrocytoma grade III with Photofrin II as a radiosensitizer. A case report.

Schaffer M1, Hofstetter A, Ertl-Wagner B, Batash R, Pöschl J, Schaffer PM.Author information 1Department of Oncology, Baruch Padeh Medical Center, Bar-Ilan School of Medicine, Poria, Israel, mschaffer@poria.health.gov.il.AbstractINTRODUCTION: Astrocytomas are neoplasms that originate from glial cells. Anaplastic astrocytoma is classified as WHO III, with 27 % of the individuals with grade III astrocytoma living for at least 5 years even after treatment (radiation and chemotherapy). Photofrin II has been demonstrated to serve as a specific and selective radiosensitizing agent in both in vitro and in vivo tumor models.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al].Strahlenther Onkol.2013 Nov;189(11):972-6. doi: 10.1007/s00066-013-0430-2. Epub 2013 Oct 26.
INTRODUCTION: Astrocytomas are neoplasms that originate from glial cells. Anaplastic astrocytoma is classified as WHO III, with 27 % of the individuals with grade III astrocytoma living for at least 5 years even after treatment (radiation and chemotherapy). Photofrin II has been demonstrated to
PMID 24158603

Japanese Journal

光線力学的治療の基礎と臨床の現状 (レーザー治療技術の現状と進展)

臼田実男,石角太一郎,池田徳彦
光学 = Japanese journal of optics : a publication of the Optical Society of Japan, the Japan Society of Applied Physics 41(11), 556-560, 2012-11-00
NAID 40019487852

子宮頸部初期癌ならびに異形成に対する光線力学療法の現状と展望

坂本優,嘉屋隆介,三宅清彦,小屋松安子,茂木真,秋谷司,落合和徳,粟津邦男,田中忠夫,岡本愛光
日本レーザー医学会誌 = The Journal of Japan Society for Laser Medicine 33(2), 117-121, 2012-08-31
NAID 10031120446

Tissue damage in the canine normal esophagus by photoactivation with talaporfin sodium (laserphyrin): a preclinical study.

Horimatsu Takahiro,Muto Manabu,Yoda Yusuke,Yano Tomonori,Ezoe Yasumasa,Miyamoto Shinichi,Chiba Tsutomu
PloS one 7(6), 2012-06-00
… Photodynamic therapy (PDT) with porfimer sodium (Photofrin®) has some problems such as the requirement for shielding from light for several weeks and a high incidence of skin phototoxicity. …
NAID 120004247254

Related Pictures

★リンクテーブル★

リンク元	「ポルフィマー」「dihematoporphyrin ether」「Photofrin」

「ポルフィマー」

Porfimer sodium
Clinical data
AHFS/Drugs.com	Consumer Drug Information
Licence data	EMA:Link, US FDA:link
Pregnancy; category	US: C (Risk not ruled out);
Legal status	US: ℞-only;
Routes of; administration	Intravenous
Pharmacokinetic data
Bioavailability	NA
Protein binding	~90%
Biological half-life	21.5 days (mean)
Excretion	Fecal
Identifiers
CAS Registry Number	97067-70-4 87806-31-3
ATC code	L01XD01
PubChem	CID: 57166
DrugBank	DB00707
ChemSpider	10482283
UNII	Y3834SIK5F
ChEMBL	CHEMBL1201707
Chemical data
Formula	C68H74N8O11 (for n=0)
Molecular mass	1179.36 g/mol (for n=0)
	SMILES [Na+].OC(=O)CC\C2=C(/C)c1cc%10nc(cc4nc(cc3nc(cc2n1)c(CCC(O)=O)c3C)/C(=C4/C)C(C)OC(C)c9c5nc(cc8nc(cc7nc(cc6nc(c5)C(\C)=C6\C(C)O)c(C)c7CCC(O)=O)C(\CCC(O)=O)=C8\C)c9C)c(C(C)O)c%10C ;
	InChI InChI=1S/C68H74N8O11.Na/c1-29-41(13-17-61(79)80)53-28-56-44(16-20-64(85)86)32(4)48(72-56)24-59-68(36(8)52(76-59)25-58-65(37(9)77)33(5)49(73-58)21-45(29)69-53)40(12)87-39(11)67-35(7)50-22-46-30(2)42(14-18-62(81)82)54(70-46)27-55-43(15-19-63(83)84)31(3)47(71-55)23-57-66(38(10)78)34(6)51(74-57)26-60(67)75-50;/h21-28,37-40,71-73,75,77-78H,13-20H2,1-12H3,(H,79,80)(H,81,82)(H,83,84)(H,85,86);/q;+1/b45-21-,46-22-,47-23-,48-24-,49-21-,50-22-,51-26-,52-25-,53-28-,54-27-,55-27-,56-28-,57-23-,58-25-,59-24-,60-26-; ; Key:CGQHMICGJYKFFJ-ZLJVSRBASA-N ;
(what is this?) (verify)